This module presents a clinical case study to demonstrate the practical application of emerging non-hormonal therapies in a patient with VMS. It emphasizes how new options can address unmet needs ...

Understanding the evidence base for new therapies is critical for informed clinical practice. This module outlines the key efficacy and safety results from the phase 3 clinical trials of fezolinetant ...

Fezolinetant (Veozah®) and elinzanetant (Lynkuet®) represent significant advancements in the non-hormonal management of moderate to severe VMS. The effectiveness of both these therapies is based on their unique and targeted ...

In recent years, the landscape of non-hormonal drugs for VMS has expanded significantly, offering alternatives for women who are contraindicated or prefer not to use hormone therapy (HT). This module ...

With the recent authorization of fezolinetant and elinzanetant for VMS by Health Canada, it is important that clinicians understand the associated monitoring requirements. This module focuses on the specific safety ...

Fezolinetant represents a significant advancement in the non-hormonal options for managing VMS associated with menopause. This module provides a summary of clinical evidence to support clinicians in identifying patients who ...

Welcome to this foundational module on the evolving landscape of vasomotor symptom (VMS) management. To effectively manage VMS, it’s crucial to first understand the underlying biological mechanisms. This module will ...

This webinar explores a practical ethical framework for understanding how AI is reshaping healthcare, with a focus on clinical practice and clinical documentation. Using the SPECTRAILS model, the session examines ...

This short microlearning program is designed to provide healthcare professionals with essential knowledge and strategies to address the challenges of polypharmacy in chronic pain management. It focuses on minimizing risks, ...